Phasebio Pharmaceuticals Inc. landed Astrazeneca plc as the lead investor in its $40 million series C round, designed to advance its biopolymer-based drug pipeline in metabolic and specialty cardiopulmonary indications. Read More
Neuralstem Inc. shares (NYSE:CUR) crumpled on Thursday, falling 36.6 percent in heavy trading to close at $2.37 as investors mulled top-line data from a phase II dose-escalation trial of NSI-566, the company's experimental neural stem cell therapy for amyotrophic lateral sclerosis (ALS). Read More
Populations in Ebola-ravaged West Africa may face the next threat to their health – by a disease that is also making a small-scale, if much-noted, comeback in the U.S.: measles. Read More
Auris Medical Holding AG brought the long-overlooked indication of tinnitus to the fore with word that enrollment will continue in its phase III trial testing AM-101 against the disorder, since the pre-specified futility threshold was not reached. Read More
HONG KONG – South Korean pharmaceutical major Green Cross Corp. is expanding its cell therapy business to China's Guizhou Province, where the local government has welcomed the investment in an emerging new therapeutic area with great potential. Read More
Sciclone Pharmaceuticals Inc., of Foster City, Calif., reported revenues of $41.4 million for the fourth quarter of 2014, a 26.6 percent increase over $32.7 million reported for the same period in 2013, and full-year 2014 revenues of $134.8 million, a 6 percent increase over $127.1 million for 2013. Read More
Intra-Cellular Therapies Inc., of New York, completed its previously disclosed public offering of 4.75 million shares, and underwriters have exercised an option to buy 661,481 more at the same price. Read More
Acucela Inc., of Seattle, said it filed an opposition to the motion to compel a special shareholders meeting filed in Washington state court by SBI Holdings Inc. and certain affiliates and Ryo Kubota, Acucela's founder and chairman. Read More
The SEC told Gilead Sciences Inc., of Foster City, Calif., and Vertex Pharmaceuticals Inc., of Cambridge, Mass., they could not block shareholders from voting on proposals asking for greater transparency around the management and mitigation of the business risks from rapidly increasing U.S. drug prices. Read More
Bioblast Pharma Ltd., of Tel Aviv, Israel, said the FDA granted clearance for it to proceed with an investigational new drug application for the development of its chemical chaperone, Cabaletta, in patients with oculopharyngeal muscular dystrophy. Read More
Iroko Pharmaceuticals LLC, of Philadelphia, said the FDA accepted for review its new drug application for Solumatrix meloxicam, a low-dose nonsteroidal anti-inflammatory drug (NSAID) for the management of osteoarthritis pain. Read More
